NasdaqGM - Delayed Quote USD
Sage Therapeutics, Inc. (SAGE)
At close: October 22 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
97,243.00
86,455.00
7,686.00
6,308.00
1,114,200.00
--
Cost of Revenue
4,400.00
2,159.00
813.00
553.00
565.00
--
Gross Profit
92,843.00
84,296.00
6,873.00
5,755.00
1,113,635.00
--
Operating Expense
542,352.00
630,759.00
553,862.00
466,664.00
489,666.00
--
Operating Income
-449,509.00
-546,463.00
-546,989.00
-460,909.00
623,969.00
--
Net Non Operating Interest Income Expense
37,374.00
38,743.00
14,190.00
2,883.00
9,597.00
--
Other Income Expense
-33,538.00
-33,769.00
15.00
134.00
-27,493.00
--
Pretax Income
-445,673.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
--
Net Income Common Stockholders
-445,673.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
--
Diluted NI Available to Com Stockholders
-445,673.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
--
Basic EPS
-7.41
-9.05
-8.98
-7.80
11.66
--
Diluted EPS
-7.41
-9.05
-8.98
-7.80
11.43
--
Basic Average Shares
60,144.00
59,836.44
59,306.09
58,670.23
51,983.19
--
Diluted Average Shares
60,144.00
59,836.44
59,306.09
58,670.23
53,003.12
--
Total Operating Income as Reported
-482,895.00
-579,849.00
-546,989.00
-460,909.00
596,226.00
--
Total Expenses
546,752.00
632,918.00
554,675.00
467,217.00
490,231.00
--
Net Income from Continuing & Discontinued Operation
-445,673.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
--
Normalized Income
-412,287.00
-508,103.00
-532,784.00
-457,892.00
633,816.00
--
Interest Income
37,374.00
38,743.00
14,190.00
2,883.00
9,597.00
--
Net Interest Income
37,374.00
38,743.00
14,190.00
2,883.00
9,597.00
--
EBIT
-449,509.00
-546,463.00
-546,989.00
-460,909.00
623,969.00
--
EBITDA
-448,123.00
-545,070.00
-545,867.00
-456,727.00
626,599.00
--
Reconciled Cost of Revenue
4,400.00
2,159.00
813.00
553.00
565.00
--
Reconciled Depreciation
1,386.00
1,393.00
1,122.00
4,182.00
2,630.00
--
Net Income from Continuing Operation Net Minority Interest
-445,673.00
-541,489.00
-532,784.00
-457,892.00
606,073.00
--
Total Unusual Items Excluding Goodwill
-33,386.00
-33,386.00
--
--
-27,743.00
--
Total Unusual Items
-33,386.00
-33,386.00
--
--
-27,743.00
--
Normalized EBITDA
-414,737.00
-511,684.00
-545,867.00
-456,727.00
654,342.00
--
12/31/2019 - 7/18/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ACAD ACADIA Pharmaceuticals Inc.
14.52
-1.63%
CYTK Cytokinetics, Incorporated
54.94
+2.10%
AGIO Agios Pharmaceuticals, Inc.
45.38
-0.61%
APLS Apellis Pharmaceuticals, Inc.
27.60
+2.68%
VYGR Voyager Therapeutics, Inc.
6.19
-19.19%
PRAX Praxis Precision Medicines, Inc.
72.25
-1.20%
ARVN Arvinas, Inc.
26.57
+3.14%
MRNS Marinus Pharmaceuticals, Inc.
1.7500
-3.85%
AMLX Amylyx Pharmaceuticals, Inc.
4.5300
-2.79%
URGN UroGen Pharma Ltd.
12.47
-0.40%